


rw

1455/65019-CA-Z-PCT-US/JPW/AJM/CY



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Marc Feldmann, Ravinder N. Maini and  
Richard O. Williams

Serial No. : 10/762,096

Filed : January 20, 2004

For : TREATMENT OF TUMOR NECROSIS FACTOR-MEDIATED  
DISEASES

1185 Avenue of the Americas  
New York, New York 10036  
February 17, 2005

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants would like to direct the Examiner's attention to the following documents which are listed on the attached Form PTO-1449 (**EXHIBIT A**). Copies of the documents listed below as items 7 and 8 are attached hereto as **EXHIBITS 1** and **2**:

1. U.S. Patent No. 5,741,488, issued April 21, 1998  
(Feldmann, et al.);
2. U.S. Patent No. 6,270,766, issued August 7, 2001  
(Feldmann, et al.);
3. U.S. Patent No. 6,770,279, issued August 3, 2004  
(Feldmann, et al.);

Applicants : Marc Feldmann et al.  
Serial No. : 10/762,096  
Filed : January 20, 2004  
Page 2

4. U.S. Patent Application Publication No. 2002/0010180 A1, published January 24, 2002;
5. U.S. Patent Application Publication No. 2002/0068057 A1, published June 6, 2002;
6. U.S. Patent Application Publication No. US 2002/0136723 A1, published September 26, 2002;
7. St. Clair, E. W., et al., "Combination of Infliximab and Methotrexate Therapy for Early Rheumatoid Arthritis", Arthritis & Rheumatism, 50(11);3432-3443 (2004) (**EXHIBIT 1**); and
8. Klareskog, L., et al., "Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial", The Lancet, 363:675-681 (2004) (**EXHIBIT 2**).

Because the above-identified application was filed after June 30, 2003, copies of the U.S. Patents and Patent Application Publications listed as items 1-6 are not required and are not provided.

If a telephone conference would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorneys invite the Examiner to telephone them at the number provided below.

Applicants : Marc Feldmann et al.  
Serial No. : 10/762,096  
Filed : January 20, 2004  
Page 3

No fee is deemed necessary in connection with the filing of this Supplemental Information Disclosure Statement. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White  
Registration No. 28,678  
Alan J. Morrison  
Registration No. 37,399  
Attorneys for Applicant  
Cooper & Dunham LLP  
1185 Avenue of the Americas  
New York, New York 10036  
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Alan J. Morrison  
Reg. No. 37,399


Date

2/12/05

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark Office

Application Number	10/762,096
Filing Date	January 20, 2004
First Named Inventor	Marc Feldmann
Art Unit	
Examiner Name	
Attorney Docket No.	1455/65019-CA-Z- PCT-US/JPW/AJM/CY

INFORMATION DISCLOSURE STATEMENT  
(Use several sheets if necessary)

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		US-5741488	04-21-1998	Feldmann, et al.
		US-6270766	08-07-2001	Feldmann, et al.
		US-6770279	08-03-2004	Feldmann, et al.
		US-20020010180-A1	01-24-2002	Feldmann, et al.
		US-20020068057-A1	06-06-2002	Feldmann, et al.
		US-20020136723-A1	09-26-2002	Feldmann, et al.

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T <sup>6</sup>

EXAMINER  
SIGNATURE

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds of Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English Language Translation is attached.

Applicants: Marc Feldmann et al.  
Serial No.: 10/762,096  
Filed: January 20, 2004  
Exhibit A

[illegible]**DATE CONSIDERED**

\* **EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a checkmark here if English language Translation is attached.